Others reported that the high expression of SDHA was associated with a poor prognosis in breast cancer patients, an increased risk of metastasis and poor clinical outcome in uveal melanoma patients, and a shorter overall (OS) survival in head and neck cancer, while the SDHA deficiency in PDX models was linked with reduced tumor growth [46,50,51]. Here, SDHA is linked to breast carcinoma.